Clinical Trial Update: HDDO-1614 Bio Equivalence Study [Phase 1]

View source ↗

Summary

The HDDO-1614 bioequivalence study in Phase 1 for osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• HDDO-1614

Snippet

Sponsor: Hyundai Pharmaceutical Co., LTD. | Conditions: Osteoporosis | Phase 1 | Status: COMPLETED